Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from Oxford Vaccine Group and the Pandemic Sciences Institute welcomed a delegation of vaccine researchers from Belgium to further UK-Belgian collaboration on vaccine development and manufacture.

The University of Oxford this week hosted a delegation of vaccine experts from Belgium to deepen collaboration between the UK and Belgium on vaccines and life sciences. 

The delegation from Belgium, including representatives from Vaccinopolis, the Rega Institute, AstriVax and Univercells, met with senior Oxford vaccine researchers Professor Teresa Lambe OBE, Professor Dame Sarah Gilbert, Professor Sir Andrew Pollard and Professor Catherine Green OBE. 

The UK and Belgium are international leaders in biotechnology, and the visit is part of a three-day programme to learn about the UK’s national vaccine capability. Facilitated by the UK’s Department of Health and Social Care, the British Embassy in Brussels and the Belgian embassy in London, it follows a visit of UK colleagues to Belgium in November 2023.  

During the visit, the delegation toured vaccine facilities at Oxford Vaccine Group, the Pandemic Sciences Institute and the Clinical Biomanufacturing Facility. They met some of the University’s leading vaccine experts who are developing vaccines for diseases with pandemic potential, including Crimean-Congo haemorrhagic fever (CCHF), Junin virus, Nipah virus and Middle-East Respiratory Syndrome (MERS).  

The delegation discussed strengths of vaccine research across Europe, and the potential for further UK-Belgian cooperation on vaccine development in areas such as human challenge models. 

After the visit, Professor Teresa Lambe OBE from Oxford Vaccine Group and the Pandemic Sciences Institute at the University of Oxford said: “I’m delighted to have welcomed the Belgian delegation to the University of Oxford today for productive discussions on vaccine research.”  

“The last few years have shown us the vital importance of international collaboration in developing and testing vaccines. This visit has been an opportunity to share joint expertise and learnings, and explore the potential for future collaboration. I look forward to coalescing our expertise, and working together to safeguard human health.” 

Bart van Meerbergen, Operational Manager at Vaccinopolis said: “This was an impressive visit to the Oxford facilities. I’m very much looking forward to working together to accelerate vaccine research, which will be needed to combat future pandemics.” 

The visit concluded with a working dinner at the Belgian Embassy in London, hosted by His Excellency Mr Bruno van der Plujim, Belgium’s Ambassador to the UK. 

Similar stories

Oxford-led newborn screening pilot expanded to include all babies in England

Every newborn baby in England will be screened for spinal muscular atrophy (SMA), following the expansion of a pioneering University of Oxford-led pilot that introduced the country’s first routine test for the condition.

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Scientists in the Department of Paediatrics discover antibody combinations that block over 90% of malaria parasite growth

In an important discovery for the next-generation of malaria vaccines, University of Oxford researchers in the Department of Paediatrics, in collaboration with the Scripps Institute, have identified how antibodies can be over 90% effective at preventing malaria parasites from growing in certain combinations.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

University of Oxford launches new public awareness campaign for Neurodevelopmental Disorders

The Department of Paediatrics at the University of Oxford today announces the launch of Genes, Brains, and Breakthroughs, a new educational campaign designed to raise public awareness and understanding of neurodevelopmental disorders through a series of accessible, family-informed video resources.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.

Similar stories

Oxford-led newborn screening pilot expanded to include all babies in England

Every newborn baby in England will be screened for spinal muscular atrophy (SMA), following the expansion of a pioneering University of Oxford-led pilot that introduced the country’s first routine test for the condition.

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Scientists in the Department of Paediatrics discover antibody combinations that block over 90% of malaria parasite growth

In an important discovery for the next-generation of malaria vaccines, University of Oxford researchers in the Department of Paediatrics, in collaboration with the Scripps Institute, have identified how antibodies can be over 90% effective at preventing malaria parasites from growing in certain combinations.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

University of Oxford launches new public awareness campaign for Neurodevelopmental Disorders

The Department of Paediatrics at the University of Oxford today announces the launch of Genes, Brains, and Breakthroughs, a new educational campaign designed to raise public awareness and understanding of neurodevelopmental disorders through a series of accessible, family-informed video resources.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.